Development of a self-degradable porcine reproductive and respiratory syndrome vaccine
Self-degradable PRRSV vaccine efficiently induces immunity, eliminates ADE, and ensures the health of pigs.
Type
Tags
Applicable industry
Applications
Key innovations
The innovation of this PRRSV vaccine lies in using Sindbis virus as a "self-degrading" carrier to induce efficient cellular immunity and overcome the shortcomings of traditional vaccines. By screening for non-ADE antigenic determinants, immune enhancing effects can be avoided and safety can be improved.
Potential economic benefits
The PRRSV vaccine can significantly reduce the huge economic losses caused by the PRRSV epidemic and provide a safe and efficient vaccine solution.
Potential climate benefits
The PRRSV vaccine reduces feed consumption, breeding energy consumption and related transportation carbon emissions by improving pig herd health and production efficiency and reducing the number of dead pigs.
Solution supplier
View more
Shanghai City Academy of Agricultural Sciences
Shanghai City Academy of Agricultural Sciences is a scientific and technological innovation base serving the development of modern agriculture in Shanghai's urban areas and is committed to the safety and sustainable development of agricultural products.
Shanghai，China
Solution details
- This project belongs to the field of biology and medicine technology
- Project background and main technical invention contents
PRRSV is an encapsulated, single-stranded positive-strand RNA-coated virus that is phagocytic to a variety of macrophages, including porcine alveolar macrophages (PAM), peripheral blood monocytes, pulmonary intravascular macrophages (PIM), etc. Stimulating efficient cellular immunity is particularly important for preventing PRRSV. Based on the characteristics of PRRSV infection, we used Sindbis virus, which has a similar infection route and induces a similar cellular immune response, as a vaccine vector to build a "self-degrading" PRRSV vaccine. Sindbis virus vector is mainly used for targeted treatment of tumors. Research as a vaccine vector has achieved good results in the development of influenza vaccines. It overcomes the shortcomings of DNA vaccines, so it is an ideal, safe and effective "self-degradable" vaccine carrier.
Main technical invention contents: (1) Isolation of highly pathogenic PRRSV virus: PRRSV genomic RNA is prone to mutate and cause antigen drift, so wild and virulent strains of PRRSV are used to amplify the antigen gene;(2) Screening for antigenic determinants of antibody-free virus enhancement (ADE): PRRSV virus has antibody-dependent virus enhancement characteristics, and using antigenic determinants of antibody-free virus enhancement can avoid this phenomenon, thereby improving the immune effect of the vaccine;(3) Screening for strong SCP promoter: Based on the characteristics of mammalian gene promoters, design and screen upstream regulatory enhancing elements and core promoter elements to enhance gene transcription levels and improve protein expression;(4) Build a "self-degrading" PRRSV vaccine: Construct a Sindbis virus plasmid vector controlled by the strong SCP promoter, insert the antigenic determinant gene of antibody-independent virus enhancement (ADE) into the constructed expression vector, and add a signal peptide-encoding gene to secrete the expressed antigen protein outside the cell to improve the antibody response level;(5) In vitro cell transfection experiment to identify the structure and expression level of the antigen protein (6) Animal immunity test, animal challenge test: The virus vector is prepared through high-density bacterial fermentation, purified and formulated the vaccine. Determine cellular immunity and humoral immunity indicators and optimize the vaccine dose. Finally, pigs immunized with the "self-degradable" PRRSV vaccine were challenged with a virulent strain of PRRSV to test the protective effect and protection period. (7) Design a new DNAzyme to antagonize PRRSV infection, proving that the new DNAzyme has a good anti-PRRSV effect. - Key inventions
(1) Screening of strong SCP promoters;
(2) Self-degradable Sindbis virus vector is used in the development of PRRSV vaccines;
(3) Designing new DNAzyme to antagonize PRRSV infection;
(4) Screening for antigenic determinants that are not antibody-dependent virus enhancing. - Intellectual property rights and application promotion: 2 authorized invention patents have been obtained, and 18 articles have been published, including 5 SCI articles. SCI articles have been cited 22 times, and domestic articles have been cited 37 times. Based on the work of this project, we applied for Shanghai City Science and Technology Commission Project 2: Establishment of LAMP Gene Rapid Detection Method for Porcine Reproductive and Respiratory Syndrome Virus and Porcine Circovirus Type 2, Project Number:14140900703, and the Hospital Youth Fund Project: Inhibitory Effect of New DNAzyme on PRRSV. This project is a social welfare applied basic research. The vaccine development and veterinary drug approval process take a long time. Currently, this new vaccine has not been marketed, but the relevant technology studied in our project has been applied. Shanghai Tuoao Biotechnology Co., Ltd. has applied our construction The replicative self-degradable Sindbis virus vector expresses insulin-like growth factors; Shanghai Saisheng Biotechnology Co., Ltd. used the ESP super promoter we constructed to express OCT4, sox2, klf4 and nanog genes, induce tissue cells, and establish stem cell lines, all of which achieved certain economic benefits.
Last updated
01:01:04, Nov 08, 2025
Information contributed by
See original page on
Report